Meropenem-clavulanate: a new strategy for the treatment of tuberculosis?
The Great White Plague: Mycobacterium tuberculosis, the bacteria causing tuberculosis, is a continuing threat to global health through the emergence of resistant strains and the lack of novel therapeutic agents. Recently reported results on this important work are highlighted.
Holzgrabe
Ulrike
U
Institute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany. u.holzgrabe@pzlc.uni-wuerzburg.de
D000995:Antitubercular Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D019818:Clavulanic Acid / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D000077731:Meropenem; D009169:Mycobacterium tuberculosis; D013845:Thienamycins / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000378:metabolism
D000995:Antitubercular Agents; D004791:Enzyme Inhibitors; D013845:Thienamycins; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D001618:beta-Lactamases; D000077731:Meropenem